Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

被引：32
|
作者：
Tiacci, Enrico [1 ]
De Carolis, Luca [1 ]
Simonetti, Edoardo [1 ]
Merluzzi, Mara [1 ]
Bennati, Antonio [1 ]
Perriello, Vincenzo Maria [1 ]
Pucciarini, Alessandra [1 ]
Santi, Alessia [1 ]
Venanzi, Alessandra [1 ]
Pettirossi, Valentina [1 ]
Schiavoni, Gianluca [1 ]
Tasselli, Luisa [1 ]
Ascani, Stefano [2 ,3 ]
Volpetti, Stefano [4 ]
Falini, Brunangelo [1 ]
机构：
[1] Univ & Hosp Perugia, Hematol, Perugia, Italy
[2] Univ Perugia, Anat Pathol, Perugia, Italy
[3] Hosp Terni, Perugia, Italy
[4] Azienda Sanitaria Univ Integrata, Clin Ematol, Udine, Italy
来源：
LEUKEMIA | 2021年 / 35卷 / 11期
基金：
欧洲研究理事会;
关键词：
MELANOMA; VEMURAFENIB; DIAGNOSIS; THERAPY;
D O I：
10.1038/s41375-021-01210-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：3314 / 3318
页数：5
相关论文
共 50 条
  • [41] Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial
    Bixby, Dale
    Noppeney, Richard
    Lin, Tara L.
    Cortes, Jorge
    Krauter, Juergen
    Yee, Karen
    Medeiros, Bruno C.
    Kraemer, Alwin
    Assouline, Sarit
    Fiedler, Walter
    Dimier, Natalie
    Simmons, Brian P.
    Riehl, Todd
    Colburn, Dawn
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 595 - 598
  • [42] Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed refractory low-grade glioma.
    Kieran, Mark W.
    Bouffet, Eric
    Broniscer, Alberto
    Cohen, Kenneth J.
    Geoerger, Birgit
    Hansford, Jordan R.
    Hingorani, Pooja
    Aerts, Isabelle
    Andre, Nicolas
    Bertozzi-Salamon, Anne-Isabelle
    Dunkel, Ira J.
    Hummel, Trent Ryan
    Leary, Sarah
    Moreno, Lucas
    Russo, Mark W.
    Tseng, Lillian
    Dasgupta, Kohinoor
    Nebot, Noelia
    Whitlock, James
    Hargrave, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials
    Robak, Tadeusz
    Robak, Pawel
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (04) : 311 - 324
  • [44] Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review
    Njue, Annete
    Colosia, Ann
    Trask, Peter C.
    Olivares, Robert
    Khan, Shahnaz
    Abbe, Adeline
    Police, Rachel
    Wang, Jianmin
    Ruiz-Soto, Rodrigo
    Kaye, James A.
    Awan, Farrukh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (01): : 1 - 12
  • [45] Clinical efficacy of lenalidomide {Revlimid®} in patients with relapsed or refractory chronic lymphocytic leukemia (CLL):: Updated results of a phase II clinical trial.
    Chanan-Khan, Asher Alban
    Miller, Kena C.
    Musial, Laurie
    Padmanabhan, Swaminathan
    Lawrence, David
    Bernstein, Zale P.
    Takeshita, Kenichi
    Spaner, David
    Byrne, Catriona
    Chrystal, Cynthia
    Czuczman, Myron S.
    BLOOD, 2006, 108 (11) : 95A - 95A
  • [46] A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA
    Noppeney, R.
    Bixby, D.
    Lin, T.
    Cortes, J.
    Krauter, J.
    Yee, K.
    Medeiros, B. C.
    Kraemer, A.
    Assouline, S.
    Fiedler, W.
    Williams, S.
    Simmons, B.
    Riehl, T.
    Colburn, D.
    HAEMATOLOGICA, 2015, 100 : 380 - 380
  • [47] Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial
    Fowler, Nathan H.
    Dickinson, Michael
    Dreyling, Martin
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason P.
    Ghosh, Monalisa
    Popplewell, Leslie L.
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Ho, Joy
    Perez-Simon, Jose Antonio
    Nagle, Sarah J.
    Nastoupil, Loretta J.
    von Tresckow, Bastian
    Ferreri, Andres J. M.
    Teshima, Takanori
    Patten, Piers
    McGuirk, Joseph P.
    Petzer, Andreas
    Offner, Fritz C.
    Viardot, Andreas
    Zinzani, Pier Luigi
    Malladi, Ram
    Pacaud, Lida Bubuteishvili
    Forcina, Alessandra
    Zia, Aiesha
    Schuster, Stephen J.
    Thieblemont, Catherine
    BLOOD, 2020, 136
  • [48] Efficacy and Safety of Tisagenlecleucel in Adult Patients With Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 ELARA Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
  • [49] Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.
    Kreitman, Robert J.
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Wang, Hao-Wei
    Zhou, Hong
    Raffeld, Mark
    Xi, Liqiang
    Arons, Evgeny
    Feurtado, Julie
    James-Echenique, Lacey
    Braylan, Raul
    Calvo, Katherine R.
    Maric, Irina
    Dulau, Alina
    Pastan, Ira
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
    Hargrave, Darren R.
    Bouffet, Eric
    Tabori, Uri
    Broniscer, Alberto
    Cohen, Kenneth J.
    Hansford, Jordan R.
    Geoerger, Birgit
    Hingorani, Pooja
    Dunkel, Ira J.
    Russo, Mark W.
    Tseng, Lillian
    Dasgupta, Kohinoor
    Gasal, Eduard
    Whitlock, James A.
    Kieran, Mark W.
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7303 - 7311
12345